摘要
目的探讨柴胡疏肝散对非酒精性脂肪性肝病(NAFLD)大鼠肝组织沉默信息调节因子蛋白1(SIRT1)/p53通路相关蛋白表达的影响。方法将24只雄性SD大鼠随机分为正常对照组、模型组、柴胡疏肝散组(9.6 g·kg-1),每组8只。正常对照组给予基础饲料,模型组和柴胡疏肝散组给予高脂饲料,柴胡疏肝散组同时给予柴胡疏肝散浸膏剂灌胃。16周后处死大鼠,检测血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)含量和肝组织TC、TG含量;取肝组织行HE和油红O染色观察组织学改变;蛋白质印迹法检测肝组织SIRT1、p53、乙酰化p53(Ac-p53)蛋白表达。结果与模型组比较,柴胡疏肝散组肝组织病理学结果表明,脂质沉积明显减轻,血清LDL-C和肝组织TC、TG显著降低(P<0.05,P<0.01),肝组织SIRT1蛋白表达水平显著上调(P<0.01),而Ac-p53蛋白表达水平下调(P<0.05)。结论柴胡疏肝散能够减轻高脂饮食诱导的NAFLD大鼠肝组织脂质沉积,调控肝组织SIRT1/p53通路相关蛋白的表达水平可能是其作用机制之一。
Objective To observe the effect of Chaihu Shugan Powder(CSP)on the expression of proteins related to silent mating type information regulation 2 homolog 1(SIRT1)/p53pathway in rats with liver tissues of nonalcoholic fatty liver disease(NAFLD)rats.Methods Twenty-four male SD rats were randomly allocated to 3 groups,namely normal control group,model group and CSP group,8 in each group.Rats in normal control group were fed with regular diet,while those in other groups were fed with high-fat diet,and rats in CSPgroup were also given CSP extracts concurrently.sixteen weeks later,all rats were killed.Serum levels of total cholesterol(TC),triglyceride(TG),high density lipoprotein-cholesterol(HDL-C),low density lipoprotein-cholesterol(LDL-C),and hepatic levels of TC and TG were measured.HE staining and Oil Red 0 staining were performed to observe the changes of liver tissues.The protein expression levels of SIRT1,p53 and Ac-p53 were detected by Western blotting.Results Compared with those of the model group,hepatic stbatosis of CSP group was improved,serum LDL-C level and hepatic levels of TC and TG were decreased significantly(P<0.05,P<0.01),SIRT1protein levels in liver tissues were increased significantly(P<0.01),while those of Ac-p53 were decreased significantly(P<0.05).Conclusion CSP can ameliorate hepatic lipid accumulationin NAFLD rats induced by high-fat diet,and the mechanism might be associated with the regulation of proteins related to hepatic SIRT1/p53 pathway.
作者
邓远军
张玉佩
杨钦河
何毅芳
梁荫基
韩莉
梁曙
DENG Yuanjun;ZHANG Yupei;YANG Qinhe;HE Yifang;LIANG Yinji;HAN Li;LIANG Shul(School of Medicine,Jinan University,Guangzhou 510632 Guangdong,China;The First Affiliated Hospital of Jinan University,Guangzhou 510630 Guangdong,China)
出处
《中药新药与临床药理》
CAS
CSCD
北大核心
2016年第5期597-601,共5页
Traditional Chinese Drug Research and Clinical Pharmacology
基金
国家自然科学基金(81273617,81302878)
广东省自然科学基金(2014A030313365)
广东省科技计划项目(2013B021800164)
广东省医学科研基金项目(A2015521)
